Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Peggy, Gao"'
Autor:
Andre Lamy, Wesley Tong, Philip Joseph, Peggy Gao, Mark D. Huffman, Gholamreza Roshandel, Reza Malekzadeh, Patricio Lopez-Jaramillo, Prem Pais, Denis Xavier, Alvaro Avezum, Antonio L. Dans, Habib Gamra, Salim Yusuf
Publikováno v:
EClinicalMedicine, Vol 73, Iss , Pp 102651- (2024)
Summary: Background: Cardiovascular disease (CVD) continues to impart a large burden on the global population, especially in lower income countries where affordability limits the use of cardiovascular medicines. A fixed dose combination strategy of a
Externí odkaz:
https://doaj.org/article/9e7d66a0bee844efb88fa88dab4c5c2f
Autor:
Andre Lamy, Wesley Tong, Philip Joseph, Peggy Gao, Prem Pais, Patricio Lopez-Jaramillo, Marjan Walli-Attaei, Antonio L Dans, Denis Xavier, Shamim Talukder, Anwar Santoso, Habib Gamra, Salim Yusuf
Publikováno v:
European Heart Journal - Quality of Care and Clinical Outcomes. 8:899-908
Aims The International Polycap Study 3 (TIPS-3) trial demonstrated that a polypill containing cholesterol- and multiple blood-pressure-lowering drugs reduces cardiovascular events by 20% compared with placebo in people without cardiovascular disease.
Autor:
Paris J Baptiste, Angel YS Wong, Anna Schultze, Catherine M Clase, Clémence Leyrat, Elizabeth Williamson, Emma Powell, Johannes FE Mann, Marianne Cunnington, Koon Teo, Shrikant I Bangdiwala, Peggy Gao, Laurie Tomlinson, Kevin Wing
BackgroundCardiovascular disease (CVD) is a leading cause of death globally. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), compared in the ONTARGET trial, each prevent CVD. However, trial populations may not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f09339023b67d14d6023ca3efd8e8519
https://doi.org/10.1101/2022.12.02.22282220
https://doi.org/10.1101/2022.12.02.22282220
Autor:
Matthias Bossard, Christopher B. Granger, Jean‐Francois Tanguay, Gilles Montalescot, David P. Faxon, Sanjit S. Jolly, Petr Widimsky, Kari Niemela, Philippe Gabriel Steg, Madhu K. Natarajan, Peggy Gao, Keith A. A. Fox, Salim Yusuf, Shamir R. Mehta
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 11 (2017)
BackgroundPrior Studies have suggested better outcomes in smokers compared with nonsmokers receiving clopidogrel (“smoker's paradox”). The impact of a more intensive clopidogrel regimen on ischemic and bleeding risks in smokers with acute coronar
Externí odkaz:
https://doaj.org/article/9df8919d77ce4ce380aa4b7c1bf81ef8
Autor:
Irina Chazova, Salim Yusuf, Eva Lonn, Jackie Bosch, Gilles R. Dagenais, Alvaro Avezum, Claes Held, Lawrence A. Leiter, Khalid Yusoff, Robert G. Hart, Prem Pais, Patricio Lopez-Jaramillo, Karen Sliwa, Ron J.G. Peters, Basil S. Lewis, Peggy Gao, Kamlesh Khunti, William D. Toff, Christopher M. Reid, Jun Zhu
Publikováno v:
Repositorio Universidad de Santander
Universidad de Santander
instacron:Universidad de Santander
Stroke, 52(8), 2494-2501. Lippincott Williams and Wilkins
Universidad de Santander
instacron:Universidad de Santander
Stroke, 52(8), 2494-2501. Lippincott Williams and Wilkins
Digital
Background and Purpose: The HOPE-3 trial (Heart Outcomes Prevention Evaluation–3) found that antihypertensive therapy combined with a statin reduced first stroke among people at intermediate cardiovascular risk. We report secondary ana
Background and Purpose: The HOPE-3 trial (Heart Outcomes Prevention Evaluation–3) found that antihypertensive therapy combined with a statin reduced first stroke among people at intermediate cardiovascular risk. We report secondary ana
Autor:
Gilles R Dagenais, Prem Pais, Peggy Gao, Gholamreza Roshandel, Reza Malekzadeh, Philip Joseph, Salim Yusuf
Publikováno v:
Heart. :heartjnl-2022
ObjectiveTo evaluate the effects of fixed dose combination (FDC) medications on cardiovascular outcomes in different age groups in an individual participant meta-analysis of three primary prevention randomised trials.MethodsParticipants at intermedia
Autor:
Johannes F.E. Mann, Philip Joseph, Peggy Gao, Prem Pais, Jessica Tyrwhitt, Denis Xavier, Tony Dans, Patricio Lopez Jaramillo, Habib Gamra, Salim Yusuf
Publikováno v:
Kidney international.
Patients with chronic kidney disease (CKD) carry a high cardiovascular (CV) risk. Since whether this risk is reduced by aspirin is unclear, we examined if the effect of aspirin on cardiovascular outcomes varied by baseline kidney function in a primar
Autor:
Johannes F E Mann, Philip Joseph, Peggy Gao, Prem Pais, Denis Xavier, Tony Dans, Patricio Lopez Jaramillo, Habib Gamra, Jessica Tyrwhitt, Salim Yusuf
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS Subjects with CKD carry a high (CV) risk. Whether this risk is blunted by aspirin is controversial. We examined CV outcomes of CKD participants of the TIPS3 trial. METHOD The International Polycap Study3 (TIPS3) randomized people
Autor:
Peggy Gao, Tomas C. Walker, Sarah Puhr, Mark Derdzinski, John B. Welsh, Claudia Graham, Terri Kang Johnson
Publikováno v:
Diabetes Technology & Therapeutics
Background: Accuracy and feature sets of continuous glucose monitoring (CGM) systems may influence device utilization and outcomes. We compared clinical trial accuracy and real-world utilization and effectiveness of two different CGM systems. Materia
Publikováno v:
Journal of Diabetes Science and Technology. :193229682210998
Background: Between-system differences for continuous glucose monitoring (CGM) devices have important clinical consequences. Purpose: Here we review attributes of Dexcom’s fifth-, sixth-, and seventh-generation (G5, G6, and G7) CGM systems. Methods